Imbria Pharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Imbria Pharmaceuticals is a privately held clinical-stage biotechnology company based in Framingham, Massachusetts, focused on developing therapies for life-altering cardiometabolic disorders by improving cellular energy production in cardiovascular disease. Its lead candidate, ninerafaxstat, is in Phase 2 trials across three indications: nHCM, stable angina, and HFpEF, reflecting an approach that targets energetic impairment as a driver of symptoms and functional deficits. The company’s work sits at the intersection of cardiovascular medicine and cellular energetics, aiming to restore or enhance the heart’s energy production to improve patient outcomes.

Within the biotechnology research industry, Imbria pursues a focused clinical program that seeks to address energy metabolism in heart disease rather than broader disease categories. A notable development occurred in October 2025, when Imbria announced a partnership with the Hypertrophic Cardiomyopathy Association to advance research and patient engagement related to hypertrophic cardiomyopathy.

Get verified Imbria Pharmaceuticals emails free

Company overview Employee directory